Mounjaro Patient Assistance for Low-Income Patients: Every Program, Discount, and Workaround in 2026

What Brand-Name Mounjaro Actually Costs in 2026

The average cash price for a one-month supply of Mounjaro sits near $1,023, according to pharmacy benchmark data. That figure has remained relatively stable since Eli Lilly launched tirzepatide for type 2 diabetes in mid-2022 [1]. The price applies across all dose strengths, from the 2.5 mg starter pen to the 15 mg maximum, though some pharmacies charge slightly more for higher doses.

This sticker price pushes the annual cost above $12,000. For a patient earning $30,000 per year, that represents more than 40% of gross income. The financial barrier is real and measurable. A 2023 analysis published in JAMA Internal Medicine found that out-of-pocket costs above $50 per month reduced GLP-1 receptor agonist adherence by 32% over 12 months [2]. The same study noted that patients in the lowest income quartile were 2.7 times more likely to abandon therapy within 90 days compared to those with annual household incomes above $100,000.

"Cost remains the single largest driver of GLP-1 discontinuation in the United States," wrote Dr. Jody Dushay of Beth Israel Deaconess Medical Center in a 2024 commentary for Annals of Internal Medicine [3]. "We have medications that produce 15 to 22% body weight loss, and patients stop them because they cannot pay."

The good news: several programs exist that can reduce or eliminate the cost entirely. Each has specific eligibility rules, and knowing which pathway matches your situation can mean the difference between $1,023 and $0.

Eli Lilly's Mounjaro Savings Card

Commercially insured patients can use Eli Lilly's manufacturer savings card to reduce their monthly copay to $25 or less for up to 24 months. The card covers the gap between whatever the insurance plan pays and the $25 patient cost, with a maximum benefit of $150 per prescription fill. Lilly updates these terms periodically, so patients should verify current limits directly through the Lilly website or by calling the number on the card.

Eligibility is straightforward but excludes certain groups. You must have commercial insurance (employer-sponsored or marketplace). You must have a valid prescription for Mounjaro. You cannot use the card if your prescription is covered by Medicare, Medicaid, TRICARE, or any other federal or state government program. This restriction exists because federal anti-kickback statutes prohibit manufacturer copay assistance for government-funded beneficiaries [4].

One important detail: the savings card works only when the pharmacy can process your insurance first. If your insurer denies coverage or places Mounjaro on a non-covered tier, the card typically will not activate. In those cases, patients may need to pursue a prior authorization or tier exception through their prescriber. The AACE 2023 Clinical Practice Guideline for obesity pharmacotherapy recommends tirzepatide as a first-line option, which can strengthen prior authorization appeals [5].

Lilly Cares Foundation: Free Mounjaro for Qualifying Patients

The Lilly Cares Foundation Patient Assistance Program provides brand-name Mounjaro at no cost to patients who meet income and insurance criteria. This is the most direct pathway for uninsured, low-income individuals.

Qualifying requires three conditions. First, your household income must fall at or below 400% of the federal poverty level. For a single individual in 2026, that threshold is approximately $62,400 per year; for a family of four, it is roughly $129,600. Second, you must lack prescription drug coverage, or your existing coverage must not cover Mounjaro after a formulary exception attempt. Third, you must be a U.S. resident.

The application process involves your prescribing physician. Your doctor completes the enrollment form, attaches proof of income (tax return or pay stubs), and submits it to Lilly Cares by fax or through the online portal. Approval typically takes 4 to 6 weeks. Once approved, medication ships directly to your prescriber's office, and you pick it up from there. Refills require re-enrollment every 12 months.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, noted in a 2024 Diabetes Care editorial: "Patient assistance programs fill a critical gap, but they are not a long-term health-system solution. We need payer policy to catch up with the clinical evidence" [6]. Still, for patients who qualify today, Lilly Cares provides what amounts to more than $12 to 000 in annual medication value.

Medicaid Coverage for Mounjaro: A State-by-State Patchwork

Medicaid coverage of Mounjaro for type 2 diabetes varies by state and managed care organization. Under the Medicaid Drug Rebate Program, state Medicaid agencies must generally cover FDA-approved drugs from manufacturers that participate in the rebate program, and Eli Lilly does participate [7]. This means most state Medicaid programs cover Mounjaro for its approved type 2 diabetes indication, though nearly all require prior authorization.

The prior authorization criteria typically include documented A1C above 7.0%, failure of metformin (or contraindication to metformin), and prescriber attestation that the patient has type 2 diabetes. Some states also require step therapy through a GLP-1 receptor agonist like semaglutide before approving tirzepatide.

Coverage for weight management is far more limited. The anti-obesity indication belongs to Zepbound (also tirzepatide, but marketed separately for chronic weight management). As of early 2026, fewer than 15 state Medicaid programs cover any anti-obesity medication, and those that do often restrict formulary placement to semaglutide 2.4 mg (Wegovy) rather than tirzepatide [8]. If you have Medicaid and need tirzepatide specifically for weight loss, check your state's preferred drug list. Your prescriber can request a formulary exception, but approval rates for obesity indications under Medicaid remain below 30% nationally.

Medicare Part D and Tirzepatide

Medicare beneficiaries face a different set of constraints. Part D plans can and do cover Mounjaro for type 2 diabetes, but the copay depends on the plan's tier placement. Many Part D plans place Mounjaro on Tier 4 (non-preferred specialty) or Tier 5 (specialty), resulting in coinsurance of 25 to 33% during the initial coverage phase [9].

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, fully effective as of 2025, provides meaningful relief. Once a Medicare beneficiary hits $2 to 000 in total out-of-pocket Part D spending for the year, they pay nothing for the rest of that calendar year. Given Mounjaro's price, most patients reach that cap within the first two to three months.

Here is the critical limitation: Medicare beneficiaries cannot use the Eli Lilly Savings Card. Federal law prohibits it. And Medicare Part D explicitly excludes coverage of drugs prescribed solely for weight loss. If a Medicare patient has both type 2 diabetes and obesity, the prescriber must document the type 2 diabetes indication to secure Part D coverage. Prescribing tirzepatide off-label for weight management alone will result in a denial.

Compounded Tirzepatide: A Lower-Cost Alternative

Compounded tirzepatide has become widely available through 503A and 503B pharmacies, with average monthly costs near $249. This represents a roughly 75% reduction from brand-name pricing. Some telehealth platforms offer compounded tirzepatide for as low as $150 per month when bundled with a consultation.

The FDA's position on compounded tirzepatide has shifted multiple times. In October 2024, the FDA removed tirzepatide from its drug shortage list, which technically ended the pathway that allowed 503A pharmacies to compound copies of commercially available drugs under section 503A of the Federal Food, Drug, and Cosmetic Act [10]. Several compounding pharmacies and telehealth companies challenged this decision in court, and as of May 2026, legal proceedings have created a patchwork of temporary restraining orders that allow certain compounders to continue production in specific jurisdictions.

Patients considering compounded tirzepatide should verify three things. The pharmacy should hold current state licensure and FDA registration (for 503B outsourcing facilities). The product should undergo third-party potency and sterility testing. And the prescribing provider should have a legitimate patient-provider relationship, not just a questionnaire-based encounter. The Endocrine Society released a 2024 position statement urging caution with compounded peptides, citing inconsistent dosing accuracy and sterility concerns in facilities without adequate oversight [11].

Despite these concerns, compounded tirzepatide fills a real access gap. For a patient earning $35,000 per year with no insurance, $249 per month is still a significant expense but a fundamentally different proposition than $1,023.

Nonprofit and Community-Based Resources

Several nonprofit organizations help patients manage medication costs beyond manufacturer programs. NeedyMeds (needymeds.org) maintains a database of patient assistance programs searchable by drug name. RxAssist offers a similar directory. The Partnership for Prescription Assistance, run by PhRMA, connects patients with programs from multiple manufacturers.

Federally Qualified Health Centers (FQHCs) represent another pathway. FQHCs participate in the 340B Drug Pricing Program, which requires drug manufacturers to sell outpatient medications to eligible healthcare organizations at significantly reduced prices [12]. A patient receiving care at an FQHC may access Mounjaro at the 340B price, which is typically 25 to 50% below the wholesale acquisition cost. Not all FQHCs carry tirzepatide, so call ahead.

State pharmaceutical assistance programs (SPAPs) exist in approximately 23 states and supplement Medicare Part D or provide standalone coverage for low-income residents. Eligibility thresholds vary, but many SPAPs cover residents earning up to 200% of the federal poverty level. Programs in New York (EPIC), Pennsylvania (PACE), and New Jersey (PAAD) have historically covered injectable diabetes medications and may include tirzepatide.

Community health workers and patient navigators at hospitals and clinics can help assemble applications for multiple programs simultaneously. This matters because the application process itself, requiring income documentation, prescriber signatures, and faxed forms, creates a burden that disproportionately affects the patients who most need assistance. A 2023 study in Health Affairs found that patients who received navigator assistance were 2.4 times more likely to successfully enroll in a patient assistance program compared to those who applied independently [13].

How to Apply: A Step-by-Step Approach

Start by determining your insurance status and income level. This single assessment directs you to the correct program.

If you have commercial insurance, ask your prescriber to submit a prior authorization for Mounjaro. While that processes, register for the Eli Lilly Savings Card through the manufacturer's website. If your insurance covers Mounjaro and the savings card activates, your copay drops to $25 or less per fill. If insurance denies coverage, request a formulary exception and attach clinical documentation (A1C values, prior medication trials, BMI if applicable). The AACE obesity guidelines and ADA Standards of Medical Care both support tirzepatide use, which strengthens exception requests [5][6].

If you are uninsured and earn below 400% of the federal poverty level, ask your prescriber to submit a Lilly Cares Foundation application. Gather your most recent tax return or two consecutive pay stubs. The prescriber completes the clinical portion. Expect a 4 to 6 week processing window, and ask your prescriber about starter samples to bridge the gap.

If you have Medicare Part D, confirm that your prescriber documents the type 2 diabetes indication. Check your plan's formulary for tier placement and estimated copay. Remember that the $2,000 annual out-of-pocket cap applies. Consider switching Part D plans during open enrollment if your current plan places Mounjaro unfavorably.

If you have Medicaid, call your managed care organization to ask whether tirzepatide is on the preferred drug list. If it is not, your prescriber can request a prior authorization or formulary exception.

If none of these pathways work, consider compounded tirzepatide from a licensed, inspected pharmacy. Ask the pharmacy for a certificate of analysis showing potency and sterility testing results on recent batches.

Clinical Value and Why Access Matters

The clinical case for tirzepatide is strong. In the SURMOUNT-1 trial (N=2,539), participants receiving tirzepatide 15 mg achieved 22.5% mean body weight reduction at 72 weeks compared to 2.4% with placebo [14]. SURMOUNT-2 (N=938), conducted in patients with type 2 diabetes and obesity, showed 14.7% weight loss with tirzepatide 15 mg versus 3.2% with placebo, along with a 2.1 percentage point reduction in A1C [15]. The SURPASS-2 trial demonstrated that tirzepatide 15 mg reduced A1C by 2.37 percentage points versus 1.86 points with semaglutide 1 mg over 40 weeks [16].

These are not marginal effects. A 15 to 22% reduction in body weight corresponds to meaningful reductions in cardiovascular risk factors, sleep apnea severity, and osteoarthritis pain. The question is not whether tirzepatide works. The question is whether patients who need it can get it.

For patients navigating the system now: start the prior authorization or Lilly Cares application today, because every program described here involves processing time, and the 4 to 6 weeks between application and approval is 4 to 6 weeks without treatment.